Economic Consequences of Treating Type-2 Diabetes Mellitus in a Private Hospital: A Fiscal, Analytical Approach (2013-2017)
Correspondence Address :
Trung Quang Vo,
Department of Pharmacy Administration, Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City,
Ho Chi Minh City 700000, Vietnam.
Introduction: Spread and the costs of Type-2 Diabetes Mellitus (T2DM) treatment are a burden on both Vietnamâ€™s nascent economy and its society.
Aim: Cost study with T2DM patients to evaluate the economicconsequence changes in T2DM treatment and strengthen the economic evidence base further.
Materials and Methods: This retrospective study was based on perspectives of patients and third-party payers using ICD 10 code to filter data from the electronic medical records database. It estimated the overall economic impact, accounting for spillovers through the economy at a private hospital from January 2013 to December 2017.
Results:The cases of 120,257 T2DM patients receiving treatment at a private hospital resulted in per patient expenditure of 29.0Â±11.5 USD (95% CI: 29.0-29.1) and 348.6Â±137.5 USD every year. The T2DM patients showed a higher prevalence of hypertension (64.1%), disorders of lipoprotein metabolism (42.5%) and gastritis (22.8%). The mean total cost for patients without any comorbidities was almost 27.1Â±10.8 USD (95% CI: 26.9-27.2) per month, while those having at least one comorbidity spent more (=28.8 USD per month). The cost of drug and related products were 3,082,452.0 USD (87.4%), in which sulfonylurea (18.2%) and metformin (10.9%) were primarily responsible.
Conclusion: From the results of the present study, it can be concluded that the direct medical costs for T2DM treatment in a private Vietnamese hospital are higher than the corresponding costs for a public hospital and T2DM will continue to be a heavy burden on health budgets.
Cost of illness, Diabetes mellitus, Economic burden, Hospital, Vietnam
Date of Submission: Apr 07, 2018
Date of Peer Review: Apr 30, 2018
Date of Acceptance: May 09, 2018
Date of Publishing: Jun 15, 2018
Financial OR OTHER COMPETING INTERESTS: None.
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)